News & Updates

Show Multimedia Only

Insulinemic lifestyle pattern ups risk of endometrial cancer

14 Jun 2025

A lifestyle pattern with higher insulinemic potential may predispose an individual to endometrial cancer (EC), suggests a study.

Insulinemic lifestyle pattern ups risk of endometrial cancer

14 Jun 2025

Chemo-free triplet regimen shows antitumour activity in HR+, HER2+ breast cancer

14 Jun 2025

Treatment with the combination of zanidatamab plus palbociclib and fulvestrant is safe and demonstrates promising antitumour activity in patients with HR-positive, HER2-positive advanced or metastatic breast cancer, according to a phase IIa study.

Chemo-free triplet regimen shows antitumour activity in HR+, HER2+ breast cancer

14 Jun 2025

Ultrasensitive ctDNA detection predicts breast cancer relapse

13 Jun 2025 by

A molecular residual disease (MRD) assay powered by whole genome sequencing (WGS) successfully detects breast cancer relapse, improving lead times for circulating tumour DNA (ctDNA) detection years ahead of clinical recurrence based on imaging.

Ultrasensitive ctDNA detection predicts breast cancer relapse

13 Jun 2025

Healthy lifestyle behaviours protective against breast cancer in postmenopausal women

13 Jun 2025

Postmenopausal women who engage in healthy lifestyle behaviours appear to have a reduced risk of breast cancer, regardless of race and ethnicity and hormone receptor status, according to a study.

Healthy lifestyle behaviours protective against breast cancer in postmenopausal women

13 Jun 2025

PFS, OS in unresectable HCC prolonged with anlotinib plus penpulimab

12 Jun 2025

In the treatment of patients with unresectable hepatocellular carcinoma (HCC), anlotinib plus pepulimab appears to significantly increase progression-free survival (PFS) and overall survival (OS) compared with sorafenib, as shown in the results of the phase III APOLLO study conducted in China.

PFS, OS in unresectable HCC prolonged with anlotinib plus penpulimab

12 Jun 2025

Low-carb, animal fat/protein-heavy diet poses increased bladder cancer risk

12 Jun 2025 by

A low-carbohydrate diet (LCD), particularly when its fat and protein sources are predominantly animal-based, may contribute to increased risk of bladder cancer among Chinese Singaporeans, according to new research.

Low-carb, animal fat/protein-heavy diet poses increased bladder cancer risk

12 Jun 2025

Timely rectal cancer treatment extends survival outcomes

12 Jun 2025

The timing of rectal cancer treatment is crucial in improving patient survival, according to a study.

Timely rectal cancer treatment extends survival outcomes

12 Jun 2025

SHR-A1811 shows promise vs HER2-positive breast cancer

12 Jun 2025 by

The third-generation human epidermal growth factor receptor 2 (HER2)-directed antibody‒drug conjugate (ADC) SHR-A1811 has passed its phase II trial, demonstrating safety and efficacy in the neoadjuvant setting for patients with HER2-positive breast cancer.

SHR-A1811 shows promise vs HER2-positive breast cancer

12 Jun 2025

$CAR T-cell therapy offers survival benefits in refractory B-cell ALL$

CAR T-cell therapy offers survival benefits in refractory B-cell ALL

12 Jun 2025

Chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukaemia (r/r B-ALL) demonstrates efficacy with high rates of durable remissions, as shown in a recent meta-analysis.

CAR T-cell therapy offers survival benefits in refractory B-cell ALL

12 Jun 2025

First-line osimertinib plus chemotherapy further extends PFS in advanced EGFR-mutated NSCLC

12 Jun 2025 by

The third-generation EGFR tyrosine kinase inhibitor (TKI), osimertinib, is preferred over earlier-generation EGFR TKIs as the first-line agent in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). In an interview with MIMS Oncology, Dr James Ho, Specialist in Respiratory Medicine in Hong Kong, discussed the positive survival outcomes associated with first-line treatment with osimertinib plus chemotherapy together in patients with advanced EGFR-mutated NSCLC, and shared which patients may benefit from this upfront combination treatment strategy.

First-line osimertinib plus chemotherapy further extends PFS in advanced EGFR-mutated NSCLC

12 Jun 2025

News & Updates

Filter by Specialty:

Specialty:

Insulinemic lifestyle pattern ups risk of endometrial cancer

Insulinemic lifestyle pattern ups risk of endometrial cancer

Chemo-free triplet regimen shows antitumour activity in HR+, HER2+ breast cancer

Chemo-free triplet regimen shows antitumour activity in HR+, HER2+ breast cancer

Ultrasensitive ctDNA detection predicts breast cancer relapse

Ultrasensitive ctDNA detection predicts breast cancer relapse

Healthy lifestyle behaviours protective against breast cancer in postmenopausal women

Healthy lifestyle behaviours protective against breast cancer in postmenopausal women

PFS, OS in unresectable HCC prolonged with anlotinib plus penpulimab

PFS, OS in unresectable HCC prolonged with anlotinib plus penpulimab

Low-carb, animal fat/protein-heavy diet poses increased bladder cancer risk

Low-carb, animal fat/protein-heavy diet poses increased bladder cancer risk

Timely rectal cancer treatment extends survival outcomes

Timely rectal cancer treatment extends survival outcomes

SHR-A1811 shows promise vs HER2-positive breast cancer

SHR-A1811 shows promise vs HER2-positive breast cancer

CAR T-cell therapy offers survival benefits in refractory B-cell ALL

CAR T-cell therapy offers survival benefits in refractory B-cell ALL

First-line osimertinib plus chemotherapy further extends PFS in advanced EGFR-mutated NSCLC

First-line osimertinib plus chemotherapy further extends PFS in advanced EGFR-mutated NSCLC